This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Long-tErm Follow-uP of antithrombotIc Management Patterns In Acute CORonary Syndrome Patients in Asia (EPICOR ASIA)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: May 23, 2011
Last updated: June 13, 2014
Last verified: June 2014
The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.

Acute Coronary Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • short- and long-term medication and treatment prescribed by physicians in real-life setting [ Time Frame: up to 3 years ]

Secondary Outcome Measures:
  • clinical outcome (Cardiovascular events) [ Time Frame: up to 3 years ]
  • cost of hospitalization [ Time Frame: up to 3 years ]
  • quality of life (EQ-5D questionnaire) [ Time Frame: up to 3 years ]

Enrollment: 13011
Study Start Date: June 2011
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Asian patients hospitalized for ACS within 48 hours of symptom onset and who have a final diagnosis of unstable angina (UA), STEMI or non-ST-segment elevation myocardial infarction (NSTEMI).

Inclusion Criteria:

  • Written informed consent has been provided.
  • Diagnosis of STEMI, NSTEMI or UA
  • Hospitalization for the first time within 48 hours of onset of symptoms.

Exclusion Criteria:

  • UA, STEMI, NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI UA, STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
  • Current participation in a randomised interventional clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01361386

  Show 109 Study Locations
Sponsors and Collaborators
Study Director: Guy Yeoman AstraZeneca
Study Chair: Prof. Huo Yong Peking University 1st Hospital
Study Chair: Jayanti Visvanathan AstraZeneca
  More Information

Responsible Party: AstraZeneca Identifier: NCT01361386     History of Changes
Other Study ID Numbers: NIS-CAP-XXX-2011/1
Study First Received: May 23, 2011
Last Updated: June 13, 2014

Keywords provided by AstraZeneca:
Long-term follow up
Antithrombotic management patterns
Acute Coronary Syndrome
quality of life

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on September 19, 2017